vast
major
commerci
avail
inactiv
influenza
vaccin
produc
egggrown
cellgrown
live
influenza
viru
first
step
product
process
viru
inactiv
bpropiolacton
bpl
formaldehyd
fa
recommend
product
inactiv
vaccin
mere
defin
maxim
concentr
reagent
leav
optim
process
manufactur
assess
effect
inactiv
bpl
fa
differ
influenza
viru
strain
properti
viral
formul
success
inactiv
preserv
hemagglutinin
ha
bind
abil
fusion
capac
potenti
stimul
tolllik
receptor
report
cell
line
assess
compar
properti
untreat
viru
inactiv
bpl
result
undetect
infect
level
fatreat
viru
retain
low
infecti
titer
hemagglutin
fusion
abil
highli
affect
treatment
confer
higher
inactiv
bpltreat
viru
bind
fuse
lower
degre
compar
fainactiv
sampl
hand
bplinactiv
viru
induc
higher
level
activ
fainactiv
viru
alter
caus
bpl
fa
treatment
viru
strain
depend
data
show
inactiv
procedur
tailor
viru
strain
mani
element
besid
concentr
inactiv
agent
incub
time
temperatur
buffer
viru
concentr
defin
achiev
function
product
influenza
viru
threaten
pathogen
caus
signific
morbid
mortal
worldwid
respons
year
epidem
caus
million
case
sever
ill
also
threat
potenti
cross
speci
barrier
gener
pandem
vaccin
costeffect
strategi
prevent
infect
sever
outcom
current
market
influenza
vaccin
includ
liveattenu
vaccin
whole
inactiv
viru
wiv
split
vaccin
subunit
vaccin
deriv
viral
particl
recombin
antigen
live
viru
vaccin
reli
attenu
eg
use
reassort
strain
backbon
coldadapt
virus
equal
compar
immunogen
type
vaccin
deriv
whole
viral
particl
crucial
step
product
viru
inactiv
gener
concept
behind
inactiv
procedur
state
intern
guidelin
provid
ema
fda
process
must
inhibit
replic
viru
without
destroy
antigen
thu
inactiv
process
caus
minimum
alter
main
antigen
influenza
viru
viral
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
prepar
inactiv
influenza
vaccin
convent
achiev
exposur
cellor
eggderiv
live
viru
betapropiolacton
bpl
formaldehyd
fa
bpl
react
readili
nucleophil
result
alkyl
acyl
product
accord
older
literatur
nucleic
acid
main
target
modif
compris
nick
crosslink
rna
viral
protein
howev
recent
find
shed
new
light
mechan
bpl
inactiv
show
also
alter
viral
protein
result
loss
ha
na
function
fusion
abil
stabil
bpl
known
depend
type
buffer
ph
mixtur
use
suggest
amount
natur
modif
viral
compon
also
determin
variabl
case
formaldehyd
viral
inactiv
achiev
alkyl
amino
sulphydril
group
protein
purin
base
fa
crosslink
viral
protein
fusion
abil
viru
affect
sinc
inactiv
critic
step
vaccin
prepar
given
manufactur
wiv
also
split
subunit
vaccin
depend
effect
viru
inactiv
major
pharmacopoeia
specifi
qualiti
standard
process
recommend
intern
guidelin
regard
inactiv
howev
quit
vagu
establish
optim
condit
left
manufactur
specif
provid
inactiv
procedur
includ
indic
temperatur
storag
maximum
amount
inactiv
agent
nonetheless
choic
variabl
concentr
viru
time
inactiv
buffer
system
use
dilut
inactiv
ph
viru
suspens
durat
incub
agent
remain
yet
unspecifi
furthermor
guidelin
clear
whether
paramet
optim
basi
vaccin
strain
concentr
viru
criterion
precis
guidelin
would
desir
order
prevent
receptor
bind
site
epitop
vaccin
destroy
inactiv
process
recent
studi
show
excess
inactiv
fa
bpl
may
caus
unanticip
modif
vaccin
antigen
result
diminish
potenc
lower
hemagglutin
titer
loss
na
activ
suggest
chemic
inactiv
might
affect
protein
conform
lead
loss
immunogen
antigen
epitop
key
surfac
protein
present
studi
present
systemat
evalu
differ
inactiv
protocol
accord
intern
guidelin
sever
influenza
viru
iav
strain
aim
compar
effect
procedur
key
properti
name
residu
infect
receptor
bind
fusion
tolllik
receptor
mediat
activ
innat
immun
mechan
determin
whether
effect
similar
differ
viru
strain
strain
use
studi
apuerto
anew
nc
vaccin
strain
backbon
produc
classic
reassort
nc
recombin
technolog
seed
virus
obtain
nation
institut
biolog
standard
control
potter
bar
unit
kingdom
propag
day
old
embryon
egg
inocul
viru
incub
h
allanto
fluid
harvest
clarifi
low
speed
centrifug
follow
two
round
purif
viru
sucros
gradient
protein
phospholipid
determin
perform
purifi
viru
use
micro
lowri
bligh
dyer
method
respect
viru
prepar
use
concentr
nmolml
phospholipid
inactiv
number
viru
particl
calcul
assum
virion
contain
phospholipid
molecul
number
deriv
use
report
composit
lipid
dri
weight
g
influenza
virion
mean
mw
lipid
gmol
calcul
take
account
possibl
contamin
viru
prepar
exosom
would
also
assum
contain
lipid
would
presum
copurifi
viru
sucros
gradient
howev
amount
exosom
expect
vari
among
viru
strain
therefor
neglect
procedur
dilut
perform
hne
buffer
mm
hepe
mm
nacl
mm
edta
ph
three
standard
inactiv
protocol
select
first
one
betapropiolacton
acro
organ
geel
belgium
use
final
concentr
vv
inactiv
done
overnight
incub
bpl
second
protocol
formaldehyd
use
final
concentr
vv
incub
h
third
protocol
also
involv
use
formaldehyd
final
concentr
vv
incub
done
h
incub
perform
constant
stir
incub
either
bpl
fa
prepar
dialyz
mwco
dialysi
tube
hepe
buffer
overnight
remov
trace
chemic
protein
phospholipid
determin
perform
dialyz
sampl
sampl
normal
concentr
nmolml
phospholipid
infect
untreat
treat
viru
sampl
test
perform
tcid
assay
mdck
cell
briefli
confluent
cultur
mdck
cell
plate
incub
twofold
serial
dilut
viru
vaccin
initi
concentr
nmolml
phospholipid
co
h
cell
wash
pb
incub
day
llwell
episerf
medium
gibco
supplement
lgml
tpcktreat
trypsin
tcid
titer
calcul
accord
trim
spearmankarb
method
hemagglutin
assay
perform
use
twofold
serial
dilut
cultur
supernat
pb
vbottom
plate
well
subsequ
guinea
pig
red
blood
cell
harlan
netherland
ad
well
plate
incub
h
room
temperatur
hemagglutin
absenc
hemagglutin
determin
visual
well
membran
fusion
assess
measur
leakag
hemoglobin
fusion
viru
particl
erythrocyt
briefli
either
guinea
pig
chicken
blood
dilut
hne
buffer
mm
hepe
mm
nacl
mm
edta
ph
centrifug
min
erythrocyt
remov
layer
peripher
blood
mononuclear
cell
wash
hne
buffer
count
brought
concentr
virusinduc
hemolysi
measur
mix
either
live
viru
vaccin
nmol
phospholipid
red
blood
cell
fusion
buffer
differ
ph
valu
rang
final
volum
ml
min
incub
suspens
centrifug
min
absorb
supernat
read
nm
autohemolysi
occur
fusion
buffer
differ
ph
valu
absenc
viru
vaccin
maxim
hemolysi
water
use
set
hemolysi
fusion
calcul
hemolysi
ph
ph
hekblu
cell
invivogen
coexpress
human
nfkbinduc
secret
embryon
alkalin
phosphatas
seap
report
gene
monitor
use
detect
medium
quantiblu
tm
hekblu
control
express
tlr
cell
cultur
accord
manufactur
instruct
cellswel
plate
plate
stimul
serial
dilut
untreat
start
dilut
vv
inactiv
start
dilut
vv
influenza
viru
initi
concentr
stock
live
inactiv
viru
nmolml
phospholipid
h
ml
supernat
ad
ml
quanti
blue
h
incub
plate
read
elisa
reader
nm
result
express
rel
activ
cell
comparison
activ
level
obtain
upon
stimul
ngml
stimul
invitrogen
order
allow
comparison
effect
differ
inactiv
process
sampl
differ
influenza
viru
strain
nc
purifi
dilut
batch
viru
concentr
sinc
amount
contamin
ovalbumin
might
differ
among
differ
viru
prepar
phospholipid
content
chosen
protein
content
quantif
viru
particl
viru
prepar
desir
concentr
nmol
phospholipidml
divid
independ
batch
inactiv
bpl
bpl
inactiv
formaldehyd
day
incub
period
other
also
inactiv
formaldehyd
day
incub
period
last
batch
kept
untreat
control
tcid
assay
mdck
cell
perform
order
determin
number
infecti
particl
viru
sampl
inactiv
initi
infect
viru
strain
differ
substanti
show
particularli
high
infect
result
particletcid
ratio
infect
low
particletcid
ratio
infect
strain
rather
similar
particletcid
ratio
inactiv
process
observ
treatment
reduc
viru
titer
least
log
case
bpl
treat
viru
found
residu
particl
independ
treat
batch
one
batch
nc
batch
show
though
low
residu
infecti
particl
tcid
ml
fa
irrespect
incub
period
unabl
complet
inactiv
viru
sampl
residu
titer
vari
tcid
ml
nc
show
lowest
show
highest
titer
case
observ
slightli
improv
reduct
residu
infect
longer
incub
period
fa
yet
effect
observ
strain
hemagglutinin
import
determin
infect
influenza
viru
role
hemagglutinin
bind
sialic
acid
receptor
infect
cell
consid
bind
reflect
function
protein
therefor
antigen
similar
one
found
live
viru
thu
assess
bind
capac
viral
hemagglutinin
inactiv
process
untreat
sampl
differ
viru
strain
bind
capac
hauml
rather
similar
nc
inactiv
sampl
percentag
rel
hemagglutin
capac
calcul
take
obtain
valu
untreat
sampl
shown
fig
treatment
caus
reduct
bind
capac
viru
inactiv
bpl
complet
loss
bind
abil
well
consist
among
batch
nc
two
batch
retain
minim
amount
bind
abil
strain
retain
bind
abil
inactiv
bpl
consist
among
batch
fa
treatment
less
effect
hemagglutin
abil
viru
strain
bpl
independ
inactiv
period
howev
effect
fa
vari
differ
viru
strain
lost
almost
entir
bind
abil
nc
retain
bind
abil
inactiv
fa
retain
bind
abil
variat
among
differ
batch
next
respons
bind
influenza
viru
target
cell
ha
also
mediat
fusion
viral
endosom
membran
infect
process
retain
function
inactiv
would
indic
ha
nativ
state
moreov
report
fusionact
whole
inactiv
viru
vaccin
better
induc
type
interferon
allow
better
induct
lymphocyt
fusion
abil
measur
incub
viral
vaccin
particl
nmol
total
phospholipid
either
guinea
pig
erythrocyt
nc
chicken
erythrocyt
follow
protocol
report
previous
shown
fig
virus
fuse
respect
erythrocyt
final
rate
fusion
vari
optim
ph
fusion
higher
ph
viru
strain
ph
bpl
complet
inhibit
fusion
abil
viru
except
minim
fusion
abil
retain
contrast
fa
inactiv
viru
particl
retain
fusion
abil
fusion
abil
sever
affect
fa
inactiv
process
appear
chang
optim
fusion
ph
caus
inactiv
sampl
fuse
lower
ph
also
loss
fusion
activ
fa
treatment
pronounc
higher
lower
ph
compar
inactiv
fa
day
day
notic
reduct
fusion
abil
viru
treat
day
notic
saw
reduct
around
fusion
abil
sampl
inactiv
day
compar
day
infect
tlr
present
antigenpres
cell
host
cell
sens
viral
compon
thu
form
import
constitu
innat
antivir
respons
particular
sensor
singlestrand
rna
present
live
viru
whole
inactiv
vaccin
activ
good
indic
abil
viru
intern
sinc
receptor
exclus
locat
endosom
membran
order
determin
whether
inactiv
procedur
would
affect
abil
virus
attach
fuse
activ
endolysosom
compart
stimul
hek
blue
cell
express
report
construct
upon
ligand
bind
untreat
inactiv
nc
result
express
percentag
activ
cell
compar
respons
fix
amount
stimul
set
activ
h
incub
medium
contain
tpcktrypsin
supernat
harvest
presenc
viru
determin
hemagglutin
assay
tcid
calcul
describ
previous
stimul
hek
blue
cell
untreat
viru
show
differ
strain
vari
larg
abil
activ
differ
viru
optim
activ
observ
differ
dilut
fig
left
panel
inactiv
mark
effect
abil
virus
stimul
activ
observ
dilut
found
optim
differ
live
virus
inactiv
nc
even
lowest
dilut
littl
activ
found
show
activ
low
dilut
bpl
inactiv
gener
preserv
abil
activ
somewhat
better
fa
thu
inactiv
protocol
strongli
reduc
abil
virus
stimul
howev
differ
among
differ
viru
strain
inactiv
crucial
illdefin
step
influenza
vaccin
prepar
therefor
intend
systemat
assess
effect
common
inactiv
procedur
differ
phase
interact
inactiv
viru
particl
cell
vitro
end
use
differ
viru
strain
order
reveal
possibl
strainspecif
differ
perform
inactiv
procedur
virus
use
singl
buffer
viru
concentr
elimin
possibl
variat
approach
also
taken
other
result
show
condit
use
bpl
quit
effici
inactiv
viral
particl
formaldehyd
although
reduc
infecti
titer
log
unabl
complet
abolish
infect
inactiv
method
caus
damag
bind
capac
viral
particl
bpl
caus
greater
loss
fa
abil
viru
fuse
target
membran
low
ph
especi
affect
bpl
treatment
fatreat
viru
still
maintain
fusion
abil
stimul
report
cell
line
also
affect
treatment
fa
inactiv
lead
greater
loss
abil
stimul
bpl
inactiv
magnitud
effect
caus
bpl
fa
treatment
appear
viru
strain
depend
differ
iav
strain
affect
vari
degre
result
clear
chemic
inactiv
impact
variou
properti
influenza
viru
treatment
depend
strain
depend
way
studi
reveal
bpl
reduc
infect
viru
undetect
level
nc
viru
show
although
low
residu
infect
fig
indic
two
strain
might
resist
inactiv
bpl
previou
studi
show
bpl
capabl
complet
inactiv
influenza
viru
howev
effect
might
vari
depend
incub
time
temperatur
review
literatur
suggest
concentr
bpl
abl
complet
inactiv
viru
incub
perform
h
temperatur
howev
concentr
bpl
use
incub
execut
like
use
studi
inactiv
period
rang
h
week
need
complet
loss
infect
contrast
bpl
fa
abl
complet
inactiv
influenza
viru
studi
seem
strainspecif
differ
sensit
fa
sinc
strain
effect
inactiv
other
strain
inactiv
improv
longer
exposur
time
fa
strain
case
varieti
differ
method
fa
inactiv
describ
literatur
method
vari
respect
exact
experiment
condit
use
includ
concentr
incub
time
case
incomplet
inactiv
report
mostli
occur
inactiv
perform
low
temperatur
done
studi
inactiv
procedur
affect
immunolog
properti
viral
antigen
determin
effect
differ
inactiv
protocol
recognit
viru
haspecif
antibodi
tri
perform
singl
radial
diffus
srid
assay
viru
sampl
inactiv
procedur
howev
rel
low
concentr
viru
use
inactiv
chosen
allow
optim
access
inactiv
agent
viral
protein
suitabl
render
reliabl
read
yet
function
properti
viral
ha
name
bind
sialic
acid
residu
target
cell
mediat
fusion
viral
endosom
membran
also
indic
func
fig
effect
inactiv
procedur
fusion
abil
fusion
abil
measur
incub
viral
vaccin
particl
nmol
total
phospholipid
either
guinea
pig
rbc
ac
chicken
rbc
de
follow
addit
fusion
buffer
reach
desir
ph
min
incub
sampl
centrifug
supernat
collect
sampl
read
nm
spectrophotomet
percentag
fusion
calcul
describ
previous
tional
unalt
protein
therefor
investig
effect
differ
inactiv
protocol
hemagglutin
hemolysi
surrog
bind
fusion
respect
observ
base
vitro
test
correl
differ
vaccin
potenc
vivo
explor
futur
experi
use
singl
radial
immunodiffus
assay
estim
protect
shown
correl
vivo
respons
recent
vitro
result
differ
manufactur
influenza
vaccin
howev
srid
assay
would
altern
method
measur
ha
integr
would
given
inform
antibodi
bind
bind
measur
hemagglutin
assay
strongli
reduc
bpl
inactiv
retain
bind
abil
fusion
even
deepli
affect
viru
strain
complet
lost
abil
fuse
treatment
bpl
viru
bind
target
membran
prerequisit
fusion
least
measur
assay
use
thu
loss
fusion
abil
expect
previou
report
shown
virus
reduc
agglutin
capac
follow
bpl
treatment
although
mani
case
inactiv
perform
differ
temperatur
incub
time
concentr
use
experi
concern
effect
bpl
fusion
abil
iav
studi
show
strain
almost
complet
inhibit
fusion
abil
bpl
concentr
rang
howev
budimir
et
al
manag
inactiv
iav
bpl
retain
fusion
abil
viru
yet
temperatur
discrep
method
could
led
observ
differ
viru
alter
effect
fa
bind
abil
fa
treat
viru
strain
still
abl
bind
erythrocyt
though
reduc
effect
except
strain
almost
complet
lost
abil
agglutin
erythrocyt
literatur
effect
fa
viru
bind
contradictori
studi
report
fa
inactiv
damag
bind
abil
viru
condit
incub
time
concentr
temperatur
similar
test
work
other
found
littl
effect
fa
treatment
though
use
differ
condit
per
temperatur
inactiv
process
conduct
fatreat
sampl
almost
complet
retain
fusion
abil
geeraedt
et
al
budimir
et
al
report
complet
loss
fusion
abil
fa
treat
viru
yet
experi
iav
deliber
treat
fa
extrem
high
concentr
prolong
exposur
inhibit
fusion
abil
previous
report
magnitud
phenotyp
immun
respons
induc
wiv
influenza
vaccin
superior
induc
split
subunit
vaccin
higher
immunogen
wiv
could
larg
attribut
activ
ssrna
present
viral
particl
furthermor
sinc
stimul
endosom
tolllik
receptor
depend
viral
endocytosi
thu
ha
function
decreas
stimul
receptor
indic
possibl
modif
surfac
antigen
induc
inactiv
procedur
therefor
investig
effect
differ
inactiv
method
trigger
inactiv
procedur
studi
markedli
reduc
often
complet
abolish
trigger
effect
bpl
inactiv
somewhat
less
sever
fa
treatment
surpris
consid
bpl
suppos
mainli
affect
nucleic
acid
fa
suppos
mainli
affect
protein
loss
trigger
necessarili
correl
loss
bind
thu
result
less
viru
reach
endosom
compart
knowledg
effect
viru
inactiv
capabl
wiv
trigger
studi
previous
earlier
studi
demonstr
wiv
capabl
activ
perform
use
much
higher
concentr
viru
mgml
viral
protein
compar
mgml
use
studi
studi
effect
inactiv
procedur
might
therefor
obscur
sever
studi
report
neg
impact
chemic
inactiv
bpl
viru
characterist
howev
studi
focus
mainli
strain
bpl
found
affect
bind
fusion
activ
modifi
protein
residu
line
find
though
studi
complianc
establish
guidelin
respect
bpl
concentr
use
differ
condit
respect
buffer
viru
concentr
incub
time
temperatur
etc
might
explain
variat
outcom
among
differ
studi
one
initi
effect
bpl
addit
decreas
ph
caus
hydrolysi
bpl
bpropion
acid
hydracryl
acid
deriv
could
lead
observ
undesir
consequ
bpl
treatment
ha
na
function
known
influenza
viru
strain
vari
sensit
low
ph
one
labil
strain
find
corrobor
earlier
observ
hand
fa
link
incomplet
inactiv
caus
outbreak
viru
infect
upon
vaccin
report
sever
virus
footandmouth
diseas
viru
fmdv
venezuelan
equin
enceph
viru
veev
also
shown
temperatur
import
factor
viru
inactiv
formaldehyd
darnel
et
al
report
sarscoronaviru
could
inactiv
low
temperatur
even
day
incub
howev
use
higher
temperatur
formaldehyd
could
inactiv
viru
day
result
contribut
increas
evid
inactiv
protocol
adapt
viru
strain
mani
import
factor
beyond
concentr
inactiv
viru
concentr
buffer
incub
time
temperatur
consid
novel
inactiv
protocol
uv
gamma
radiat
use
hydrogen
peroxid
alreadi
mention
literatur
need
thorough
test
standard
employ
context
influenza
vaccin
product
current
new
emerg
technolog
manufactur
influenza
vaccin
would
requir
inactiv
process
product
iav
protein
vitro
cultur
peptid
deriv
iav
protein
show
promis
result
yet
egg
cultur
current
cheapest
effici
way
produc
high
amount
vaccin
rel
short
amount
time
therefor
new
vaccin
product
method
compet
egg
cultur
develop
inactiv
standard
procedur
vaccin
manufactur
result
therefor
call
establish
detail
inactiv
procedur
vaccin
manufactur
search
differ
effici
inactiv
method
includ
intern
guidelin
author
declar
conflict
interest
